Cost-effectiveness analysis of Cadonilimab in first-line treatment of advanced HER2-negative gastric cancer or gastroesophageal junction cancer.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs), including Pembrolizumab, Nivolumab, Sintilimab, Tislelizumab, and Sugemalimab, have been approved in China as first-line treatments for advanced HER2-negative gastric cancer (GC) and gastroesophageal junction cancer (GEJC). However, the latest COMPASSION 15 study showed that Cadonilimab in combination with chemotherapy provided significant survival benefits.

Objective

This study aims to evaluate the cost-effectiveness of Cadonilimab plus chemotherapy versus chemotherapy alone and the ICIs approved in China for first-line treatment of advanced HER2-negative gastric cancer or gastroesophageal junction carcinoma (GC/GEJC) from the perspective of Chinese payers.

Design

The cost-effectiveness analysis.

Methods

Based on

SUBMITTER: Zhu K 

PROVIDER: S-EPMC12497967 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature